APPROVED FOR 8 INDICATIONS AND WITH MORE THAN 1 MILLION PATIENTS ON THERAPY WORLDWIDE*
Uncontrolled Moderate-to-Severe
Ages 6+ Months
Add-on Maintenance Treatment for Uncontrolled
Moderate-to-Severe Eosinophilic or Oral
Steroid Dependent
Ages 6+ Years
DUPIXENT is not used to relieve sudden breathing
problems and will not replace an inhaled rescue medicine
Add-on Maintenance Treatment for Inadequately Controlled
with high blood eosinophils
Ages 18+ Years
DUPIXENT is not used to relieve sudden breathing
problems and will not replace an inhaled rescue medicine
*The worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands,
Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, BP,
COPD, CRSwNP, CSU, PN, and EoE. Data through August 2025.
With the DUPIXENT MyWay® Copay Card, eligible patients with commercial health insurance may pay as little as $0† in copay per fill of DUPIXENT.
CHECK COPAY CARDReceive emails to help support your journey.